CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Here are some highlights from the first half of the year: ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...